Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.

Haematologica
Chi Young OkKeyur P Patel

Abstract

Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known. In this study, we evaluated 80 acute myeloid leukemia patients with known IDH1 R132 or IDH2 R140/R172 mutations and assessed their bone marrow at the time of remission to determine the potential impact of persistent IDH1/2 mutations. Approximately 40% of acute myeloid leukemia patients given standard treatment in this cohort had persistent mutations in IDH1/2 Patients with an IDH1/2 mutation had an increased risk of relapse after 1 year of follow-up compared to patients without a detectable IDH1/2 mutation (59% versus 24%; P<0.01). However, a persistent mutation was not associated with a shorter time to relapse. High IDH1/2 mutation burden (mutant allelic frequency ≥10%) did not correlate with relapse rate (77% versus 86% for patients with a low burden, i.e., mutant allelic frequency <10%; P=0.66). Persistent mutations were also observed in NPM1, DNMT3A and FLT3 during remission, but IDH1/2 mutations remained significant in predicting relapse by multivariate analysis. Flow cytometry was comparable and complementary to next-generation seq...Continue Reading

Citations

Dec 6, 2019·British Journal of Haematology·Jack GhannamChristopher S Hourigan
Mar 20, 2020·Journal of Clinical Medicine·Cristina PanuzzoDaniela Cilloni
Jun 19, 2019·Cytometry. Part B, Clinical Cytometry·Zhining ChenSa A Wang
Jan 23, 2020·Journal of Clinical Medicine·Jessica PetitiDaniela Cilloni
Dec 7, 2019·Hematology·Sylvie D Freeman, Christopher S Hourigan
Dec 30, 2020·Leukemia & Lymphoma·Diego CarbonellCarolina Martínez-Laperche
Mar 25, 2021·The Journal of Experimental Medicine·Lucille StuaniJean-Emmanuel Sarry
Apr 10, 2021·Cold Spring Harbor Molecular Case Studies·Zoltán N OltvaiPawel Mroz
Jun 3, 2021·International Journal of Molecular Sciences·Deirdra VenneyKen I Mills
Jul 17, 2021·International Journal of Laboratory Hematology·Jingtao LuHongying Chao
Aug 12, 2021·Leukemia·Luca Vincenzo CappelliAlexander Höllein
Aug 19, 2021·European Journal of Haematology·Amy SongMohammad O Hussaini

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

SAS
OncoSeek
GraphPad Prism
GraphPad
MiSeq
Integrative Genomics Viewer ( IGV
SureCall

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.